Presentation day at #AAIC24! Drop by poster # 829 and chat with our CSO, Noelle Callizot on our findings "Lecanemab induces phenotypic change in glial and microglial cells in Alzheimer’s disease models: vitro and vivo evidences." See you there!
NEURO-SYS
Recherche en biotechnologie
Gardanne, BDR 2 787 abonnés
CNS/PNS - In vitro - In vivo - Drug Development
À propos
Neuro-Sys is a research-intensive and innovative organisation specialising in pharmacology and in advanced in vitro and in vivo models of neurodegenerative diseases, mode of action research, and drug development in the CNS and PNS fields. We provide pharmacological profiles of lead compounds and explore their underlying mechanism of action and studies to determine the neuroprotective activity. We’re dedicated to providing high-level technical expertise in a collaborative relationship with our clients and accompany you along the drug development stages, from preclinical to clinical. Our expertise: › Alzheimer’s disease (AD) › Parkinson’s disease (PD) › Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease) › Multiple Sclerosis (MS) › Peripheral Neuropathies › Blood Brain Barrier DRUG DEVELOPMENT SERVICES Our experts in drug and pharmaceutical development provide expert guidance on: •The design of your drug discovery development plan (pre-clinical testing in vitro and in vivo models) •The design of your preclinical research programs (in vitro/ in vivo, mode of action) •The preclinical (Pharmacology, PK and ADME) development and early clinical designs (PoC studies) •The writing of research projects, investigator brochures (IB), IMPD, ODD submission (FDA/EMA) in neuro indication
- Site web
-
http://www.neuro-sys.com
Lien externe pour NEURO-SYS
- Secteur
- Recherche en biotechnologie
- Taille de l’entreprise
- 11-50 employés
- Siège social
- Gardanne, BDR
- Type
- Partenariat
- Fondée en
- 2013
Lieux
-
Principal
Obtenir l’itinéraire
410 Chemin Departemental 60
13120 Gardanne, BDR, FR
-
Obtenir l’itinéraire
50 Milk St, 16th floor
02109 BOSTON, MA, US
Employés chez NEURO-SYS
Nouvelles
-
NEURO-SYS takes part in BIO US in San Diego from June 3 to 6, 2024. It's a great opportunity to meet us for interesting and fruitful collaborations. https://lnkd.in/dKrXuHVa
-
-
NEURO-SYS is program partner at the 3rd annual ALS Drug Development Summit in Boston, May 21-23, 2024. Alexandre Henriques, our Director of Pharmacology and ALS expert, will be attend. Take the opportunity to discuss science and your ALS R&D projects with him. He will be supported by Lauren Currie, PhD MBA, our VP of Business Development. https://lnkd.in/gCHds7tt Not able to attend the summit, but interested in learning more? Contact us at [email protected]! #ALS
-
-
At NEURO-SYS, we are a leading preclinical CRO specialized in neurodegenerative diseases such as ALS. Our mission is to support clients in driving groundbreaking research and therapeutic discoveries for these devastating conditions. This ALS Awareness Month, we reaffirm our commitment as a strategic partner empowering biotech and pharmaceutical companies through our scientific expertise and state-of-the-art preclinical capabilities. We pioneer innovative approaches to elucidate disease biology and accelerate the evaluation of promising therapeutic candidates. From study design to execution, our specialized neurodegenerative disease focus enables us to guide clients at every step, applying scientific rigor to keep their programs on the cutting edge. Join us as we fuel pioneering research and discovery efforts to unlock a future free from the burden of ALS and related neurodegenerative diseases. https://lnkd.in/dPKfqquy #LouGehrigsDisease #HopeForACure #FightAgainstALS #ALSAwareness #EndALS #Neuroscience #ALSResearch #DrugDiscovery
-
-
Our CSO Noelle Callizot's talk today at the 12th Alzheimer’s & Parkinson’s Drug Development Summit in Boston, MA, covered "Parkinson’s disease: α-synuclein’s mechanisms of cell death in vitro and in vivo evidences." For more information about our PD models, contact us or go to www.neuro-sys.com. #Parkinson
-
-
Great success at yesterday's poster session at the 12th Alzheimer’s & Parkinson’s Drug Development Summit in Boston, MA. Our poster presented by NEURO-SYS' CSO Noelle Callizot: "Lecanemab supports phenotypic change of glial cells: evidences in an in vitro model of Alzheimer’s Disease" attracted the interest of many scientists.
-
-
NEURO-SYS is program partner at the 12th annual Alzheimer's & Parkinson's Drug Development Summit in Boston, April 23-25, 2024. Take part in our CSO Noelle Callizot's seminar: Parkinson’s Disease and a-synuclein Mechanisms of Cell Death: In Vitro and In Vivo Models (April 24th @11am). https://lnkd.in/dyygnBct Not able to attend the summit, but interested in learning more? Contact us at [email protected]!
-
-
Several job opportunities available on NEURO-SYS French site: - Senior in vivo Project Manager - Senior histology Project Manager - In vitro technician - In vivo technician Grab the opportunity! https://lnkd.in/dYveYGNP
-